-
April 1, 2013
Antibody drugs set to revive flagging migraine target
CGRP makes a comeback as antibodies advance into Phase II trials.
Read More
-
March 20, 2013
Docs Who E-Prescribe Order More Generics, Study Says
Putting drug details in front of doctors, combined with incentive programs for generics, is steering prescriptions toward low-cost medicine.
Read More
-
March 15, 2013
Eli Lilly, insurers at odds over new type of drug
One state legislator said she had never seen so many lobbyists testify on a single-issue bill.
Read More
-
March 10, 2013
Long-Term Benefits, Risks of Newest Diabetes Drugs Still Unclear
New data shows the latest class of diabetes drugs may protect against heart failure, but the long-term health benefits and risks require more study.
Read More
-
March 8, 2013
Janssen will begin clinical trials for expanded use of Xarelto blood thinner
Janssen Pharmaceuticals announced today it will launch a global research program to evaluate the expanded uses of its blood thinner Xarelto, days after the drug failed to win approval to prevent heart attacks and strokes.
Read More
-
March 5, 2013
Medivir, Gilead Oral Drug Pair Strong in HCV, Early Phase IIa
Their oral combo drug's 100 percent success rate in hepatitis C virus (HCV) patients with liver fibrosis did not do much for shares of Medivir AB and partner Gilead Sciences Inc., probably because the positive interim results from the Phase IIa trial were "baked in" by investors, who must wait to find out more.
Read More
-
March 4, 2013
Beyond Herceptin: Kadcyla Carries Torch Across Lines Of HER2 Therapy
With the approval of its Herceptin -containing antibody drug conjugate Kadcyla (T-DM1), Roche / Genentech Inc. is moving closer to the goal of managing HER2-positive breast cancer patients across multiple lines of therapy.
Read More
-
February 26, 2013
Cholesterol limits lose their lustre
Revised guidelines for heart health are set to move away from target-based approach.
Read More
-
February 21, 2013
Novo's Pain Means Sanofi Shares Gain
The FDA's recent refusal to approve Novo Nordisk's new diabetes drug puts the pricey ADRs at risk, and opens the door to more profits for rival Sanofi.
Read More
-
February 10, 2013
New Celgene drug packs punch for multiple myeloma market
The market for multiple myeloma drugs has been forecast to grow 60% by 2021, reaching more than $7 billion from about $4.4 billion.
Read More
-
February 7, 2013
Former Tennessee Health Commissioner Susan Cooper settles into new role at The Med
Susan Cooper is glad she doesn't have to answer the phone at 3 a.m. anymore. But she wants it made clear that when her phone does ring, it rings in Memphis.
Read More
-
February 1, 2013
Type 2 Diabetes Drugs Drive Sector Growth
Firms Use a Range of Strategies to Exploit a Market Expected to Grow to $157B by 2017.
Read More
-
January 22, 2013
Health insurers propose double-digit rate hikes
While premiums for many small-group plans in Illinois are expected to rise 5 percent to 7 percent this year, some consumers will be socked by double-digit rate hikes.
Read More
-
January 17, 2013
Health Plans Keep Watchful Eye on ‘New Generation’ Blood-Thinning Therapies
Nearly 60 years ago, warfarin was approved for use as a blood-thinning agent for the prevention of thrombosis and embolism in many disorders and still remains the most widely prescribed oral anticoagulant drug in the U.S.
Read More
-
January 15, 2013
Increased Uptake of Hepatitis B Drugs Expected in the Coming Years
Uptake of oral nucleoside/nucleotide analogues will increase from 2011 to 2021, according to new research from Decision Resources.
Read More